Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
Top Cited Papers
- 29 September 2014
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 40 (10), 1209-1222
- https://doi.org/10.1111/apt.12963
Abstract
Several steatosis biomarkers are available with limited independent validation. To determine diagnostic value and limitations of several steatosis biomarkers using liver biopsy as reference standard in a large cohort of patients with suspected NAFLD. Three hundred and twenty-four consecutive liver biopsies were included. Histological steatosis was categorised as none (66%). Five steatosis biomarkers were measured: fatty liver index (FLI), NAFLD liver fat score (NAFLD-LFS), hepatic steatosis index (HSI), visceral adiposity index (VAI) and triglyceride × glucose (TyG) index. Steatosis grades prevalence was: none 5%, mild 39%, moderate 30% and severe 27%. Except for VAI, the steatosis biomarkers showed a linear trend across the steatosis grades. However, their correlation with the histological amount of steatosis was only weak-moderate. All steatosis biomarkers had an adequate diagnostic accuracy for the presence of steatosis: AUROCs for FLI, LFS, HSI, VAI and TyG were 0.83, 0.80, 0.81, 0.92 and 0.90. However, their ability to quantify steatosis was poor: none of them distinguished between moderate and severe steatosis and the AUROCs for predicting steatosis >33% were 0.65, 0.72, 0.65, 0.59 and 0.59 for FLI, LFS, HSI, VAI and TyG. Both fibrosis and inflammation significantly confounded the association between steatosis biomarkers and steatosis. The steatosis biomarkers were all correlated with HOMA-IR, independent from histological steatosis. All five steatosis biomarkers can diagnose steatosis and are correlated with insulin resistance. They are confounded by fibrosis and inflammation, and do not accurately quantify steatosis; this may limit their clinical utility. More research is needed to identify truly independent and quantitative markers of steatosis.Keywords
Funding Information
- European Commission Directorate-General for Research and Innovation (HEALTH-F2-2009-241762)
This publication has 55 references indexed in Scilit:
- Extrahepatic complications of nonalcoholic fatty liver diseaseJournal of Hepatology, 2014
- Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisalJournal of Hepatology, 2013
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective StudyGastroenterology, 2011
- Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severityAnnals of Medicine, 2010
- Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic FactorsGastroenterology, 2009
- Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective studyJournal of Hepatology, 2009
- Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic PatientsDiabetes Care, 2007
- The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general populationBMC Gastroenterology, 2006
- Hepatic histology in obese patients undergoing bariatric surgeryJournal of Hepatology, 2006
- The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosisDigestive and Liver Disease, 2006